Seagen Aims To Make Tukysa First Drug For HER2-Positive Colorectal Cancer
The Phase II MOUNTAINEER trial showed a benefit for patients with HER2-positive metastatic colorectal cancer treated with the tyrosine kinase inhibitor in combination with trastuzumab.
You may also be interested in...
Merck is closing in on the acquisition of the antibody drug conjugate specialists which would help the pharma giant consolidate its presence in oncology.
A buyout of Seagen would boost Merck & Co’s goal of becoming the dominant player in oncology by 2025, but the deal is said to be far from done.
The results of DESTINY-Breast04 could impact survival for approximately 50% of patients diagnosed with metastatic breast cancer today, principal investigator Modi said at the American Society of Clinical Oncology annual meeting.